A comparative study of nafamostat mesylate and local sodium citrate anticoagulation in continuous renal replacement therapy in critically ill patients

Comparison of nafamostat mesylate and local sodium citrate anticoagulation in continuous renal replacement therapy in critically ill patients: a prospective, randomized, controlled study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082532

Enrollment

Unknown

Registered

2024-04-01

Start date

2024-04-01

Completion date

Unknown

Last updated

2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal insufficiency

Interventions

NM group:Nafamostat mesilate anticoagulation

RCA group:Regional citrate anticoagulation

Eligibility

Sex/Gender

All

Age

18 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Indications for renal replacement therapy (RRT); 3.Patients who signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe liver dysfunction; 2. Pregnant woman; 3. Contraindication for nafamostat mesylate or sodium citrate anticoagulation; 4.Patients on ECMO; 5.Patients who refuse to sign an informed consent form.

Design outcomes

Primary

Measure	Time frame
Filter life;	—

Secondary

Measure	Time frame
Complications of CRRT: bleeding complications;All-cause mortality: 28 days, 60 days, 90 days;CRRT treatment costs; Total hospitalization costs;	—

Countries

China

Contacts

Public ContactWang Xuemin

Shanghai Songjiang District Central Hospital

wangxm100@hotmail.com+86 189 1828 5282

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026